$0.00
This series examines how payments from drug companies to scientists at the National Institutes of Health cause a conflict of interest that affects health care and policy recommendations. Even under the partial reforms announced by the presidentially appointed NIH director in 2004, some NIH scientists would still be able to take compensation such as stock options and consulting fees.
Looks like you haven't made a choice yet.
